Johnson & Johnson today announced the completion of the acquisition of Actelion Ltd. for a total purchase price of approximately $30 billion in cash.

Bioverativ is buying True North Therapeutics for an upfront payment of $400 million and up to $425 million in milestones.

Celgene will acquire Acetylon Pharmaceuticals and spin off some of its pipeline into a new company, Regenacy Pharmaceuticals.

After the announcement by Biogen that it was spinning off its hemophilia business, analysts and investors are pondering, somewhat quizzically, just what it means.

Biogen Inc. plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.

Only days after Google’s Life Sciences spinoff announced its new name, Verily Life Sciences, Johnson & Johnson (JNJ) announced a collaboration with Verily to create an independent surgical solutions company, Verb Surgical Inc. In March 2015, JNJ’s Ethicon, Inc. (JNJ), a medical devices company, announced a strategic collaboration with Google Life Sciences. The focus of […]

In Tuesday’s conference call, Indianapolis-based Eli Lilly & Co. (LLY) indicated it is splitting its animal health drugs manufacturing facilities from its human drug manufacturing plants.   Bloomberg Business speculates that this is a move that might eventually lead to spinning off the division. For the moment, however, company representatives insist that the rationale is […]

November 24, 2015By Mark Terry, BioSpace.com Breaking News Staff   Now that the Pfizer (PFE)-Allergan (AGN) merger is official, the company and analysts are looking at details about the merged company splitting into two or more companies. This isn’t exactly new thinking. All throughout the three weeks of rumors, the idea that the new mega-company […]

Cambridge, Mass.-based Gurnet Point Capital announced today that it is launching a new company, Boston Pharmaceuticals, with former Sanofi (SNY) chief executive officer Chris Viehbacher to chair it. Late last year, Viehbacher was ousted by Paris-based Sanofi over battles about strategy with the company’s board. He eventually landed at Gurnet Point Capital in June of […]

Dublin-based Shire (SHPG) announced today that it will acquire Burlington, Mass.-based Dyax Corporation (DYAX) for about $5.9 billion. Shire will pay $37.30 per Dyax share in cash, totaling around $5.9 billion. In addition, if Dyax’s pipeline product, DX-2930 for the treatment of HAE, a rare, debilitating genetic inflammatory condition, is approved, Dyax shareholders will receive […]